Endocrine Society GUIDELINES Bundle (free trial)

Lipid Management in Endocrine Disorders

Endocrine Society GUIDELINES Apps brought to you free of charge courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1356565

Contents of this Issue


Page 21 of 21

106 Commerce Street, Suite 105 Lake Mary, FL 32746 TEL: 407.878.7606 • FAX: 407.878.7611 Order additional copies at GuidelineCentral.com Copyright © 2020 All rights reserved ESLIP03214 Disclaimer is pocket guide attempts to define principles of practice that should produce high-quality patient care. It focuses on the needs of primary care practice but also is applicable to providers at all levels. is pocket guide should not be considered exclusive of other methods of care reasonably directed at obtaining the same results. e ultimate judgment concerning the propriety of any course of conduct must be made by the clinician aer consideration of each individual patient situation. Neither IGC, the medical associations, nor the authors endorse any product or service associated with the distributor of this clinical reference tool. Source Connie Newman (Chair), Michael J. Blaha, Jeffrey B. Boord, Bertrand Cariou, Alan Chait, Henry Fein, Henry Ginsberg, Ira Goldberg (Co-Chair), M. Hassan Murad, Savitha Subramanian, and Lisa R. Tannock. Lipid Management in Patients with Endocrine Disorders: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2020;105(12). Abbreviations ASCVD, atherosclerotic cardiovascular disease; CAC, coronary artery calcium; CKD, chronic kidney disease; CV, cardiovascular; CVD, cardiovascular disease; FH, familial hypercholesterolemia; GHD, growth hormone deficiency; GI, gastrointestinal; EPA, eicosapentaenoic acid; HDL-C, high-density lipoprotein cholesterol; LDL, low-density lipoprotein; LDL-C, low-density lipoprotein cholesterol; Lp(a), lipoprotein(a); MetS, metabolic syndrome; PCSK9, Proprotein convertase subtilisin/kexin type 9; T1D, type 1 diabetes; T2D, type 2 diabetes; TG, triglycerides Grading System Quality of Evidence High Quality Moderate Quality Low Quality Very Low Quality Description of Evidence • Well-performed RCTs • Very strong evidence from unbiased observational studies • RCTs with some limitations • Strong evidence from unbiased observational studies • RCTs with serious flaws • Some evidence from observational studies • Unsystematic clinical observations • Very indirect evidence from observational studies Strength of Recommendation Strong (1): "ES recommends…" Benefits clearly outweigh harms and burdens or vice versa 1|⊕⊕⊕⊕ 1|⊕⊕⊕ 1|⊕⊕ 1|⊕ Conditional (2): "ES suggests…" Benefits closely balanced with harms and burdens 2|⊕⊕⊕⊕ 2|⊕⊕⊕ 2|⊕⊕ 2|⊕ Ungraded Good Practice Statement UGPS

Articles in this issue

Links on this page

Archives of this issue

view archives of Endocrine Society GUIDELINES Bundle (free trial) - Lipid Management in Endocrine Disorders